Nongenomic uterine relaxing effect of RU 486 (mifepristone) prior to its antiprogesterone activity in the human pregnancy

Steroids

Volumn 74, Issue 10-11, 2009, Pages 825-831

  Perusquía, Mercedes ^a,b   Espinoza, Julia ^a   Navarrete, Erika ^a  

^a UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^b TEXAS A AND M UNIVERSITY   (United States)

Author keywords

Antiprogesterone action; Antiprogestins; Mifepristone; Nongenomic effect; RU 486; Uterine relaxation

Indexed keywords

CALCIUM CHANNEL; CYCLOHEXIMIDE; DACTINOMYCIN; MIFEPRISTONE; MISOPROSTOL; OXYTOCIN; PROGESTERONE; PROSTAGLANDIN DERIVATIVE; PROSTAGLANDIN E2; PROSTAGLANDIN F2 ALPHA;

ARTICLE; CESAREAN SECTION; FEMALE; HUMAN; HUMAN TISSUE; MYOMETRIUM; PREGNANCY; PROTEIN SYNTHESIS; UTERUS CONTRACTILITY; UTERUS RELAXATION;

CALCIUM; CALCIUM CHANNEL BLOCKERS; ELECTRIC CONDUCTIVITY; FEMALE; HORMONE ANTAGONISTS; HUMANS; ION CHANNEL GATING; MIFEPRISTONE; MUSCLE RELAXATION; OXYTOCIN; POTASSIUM CHLORIDE; PREGNANCY; PROGESTERONE; PROSTAGLANDINS; PROTEIN BIOSYNTHESIS; TERM BIRTH; TIME FACTORS; TRANSCRIPTION, GENETIC; UTERINE CONTRACTION; UTERUS;

EID: 67651119863     PISSN: 0039128X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.steroids.2009.05.002     Document Type: Article

References (27)

1. Csapo A.I. Progesterone block. Am J Anat 98 (1956) 273-291
2. Perusquía M. Nongenomic action of steroids in myometrial contractility. Endocrine 15 (2001) 63-72
3. Perusquía M., García-Yañez E., Ibáñez R., and Kubli-Garfias C. Non-genomic mechanism of action of Δ-4 and 5-reduced androgens and progestins on the contractility of the isolated rat myometrium. Life Sci 47 (1990) 1547-1553
4. A receptor systems. Biol Reprod 45 (1991) 266-272
5. Perusquía M., and Jasso-Kamel J. Influence of 5α- and 5β-reduced progestins on the contractility of isolated human myometrium at term. Life Sci 68 (2001) 2933-2944
6. Ruddock N.K., Shi S.Q., Jain S., Moore G., Hankins G.D., Romero R., et al. Progesterone, but not 17-alpha-hydroxyprogesterone caproate, inhibits human myometrial contractions. Am J Obstet Gynecol 199 (2008) 391-397
7. Swahn M.L., and Bygdeman M. The effect of the antiprogestin RU 486 on uterine contractility and sensitivity to prostaglandin and oxytocin. Br J Obstet Gynaecol 95 (1988) 126-134
8. Bygdeman M., and Swahn M.L. Progesterone receptor blockage: effect on uterine contractility and early pregnancy. Contraception 32 (1985) 45-51
9. Cameron I.T., Michie A.F., and Baird D.T. Therapeutic abortion in early pregnancy with antiprogestogen RU 486 alone or in combination with prostaglandin analogue (gemeprost). Contraception 34 (1986) 459-468
10. UK Multicentre Trial. The efficacy and tolerance of mifepristone and prostaglandin in first trimester termination of pregnancy. Br J Obstet Gynecol (1990) 480-486
11. World Health Organization. Termination of pregnancy with reduced dose of mifepristone. Br Med J (1993) 532-537
12. Ulmann A., Silvestre L., Chemama L., Rezvani Y., Renault M., Aguillaume C.J., et al. Medical termination of early pregnancy with mifepristone (RU 486) followed by a prostaglandin analogue. Study in 16,369 women. Acta Obstet Gynecol Scand 71 (1992) 278-283
13. Garfield R.E., Blennerhassett M.G., and Miller S.M. Control of myometrial contractility: role and regulation of gap junctions. Oxf Rev Reprod Biol 10 (1988) 436-490
14. Norman J.E., Thong K.J., and Baird D.T. Uterine contractility and induction of abortion in early pregnancy by misoprostol and mifepristone. Lancet 338 (1991) 1233-1236
15. Rådestad A., Christensen N.J., and Strömberg L. Induced cervical ripening with mifepristone in first trimester abortion. A double-blind randomized biomechanical study. Contraception 38 (1988) 301-312
16. World Health Organization. Cervical ripening with mifepristone (RU 486) in late first trimester abortion. Contraception (1994) 461-475
17. Perusquía M., Navarrete E., Jasso-Kamel J., and Montaño L.M. Androgens induce relaxation of contractile activity in pregnant human myometrium at term: a nongenomic action on L-type calcium channels. Biol Reprod 73 (2005) 214-221
18. Perusquía M., and Kubli-Garfias C. Progesterone-like relaxant effect of RU 486 in the rat myometrium. Life Sci 54 (1994) 1501-1506
19. Parra J., Cantabrana B., and Hidalgo A. Mechanism of mifepristone-induced spasmolytic effect on isolated rat uterus. Life Sci 66 (2000) 2563-2569
20. Waring P. DNA fragmentation induced in macrophages by gliotoxin does not require protein synthesis and is preceded by raised inositol triphosphate levels. J Biol Chem 265 (1990) 14476-14480
21. Perry R.P., and Kelley D.E. Inhibition of RNA synthesis by actinomycin D: characteristic dose-response of different RNA species. J Cell Physiol 76 (1970) 127-139
22. 2 release. Prostaglandins 44 (1992) 443-455
23. 2 release from human myometrium: mechanisms of action. J Steroid Biochem Mol Biol 59 (1996) 63-73
24. Wolf J.P., Sinosich M., Anderson T.L., Ulmann A., Baulieu E.E., and Hodgen G.D. Progesterone antagonist (RU 486) for cervical dilation, labor induction, and delivery in monkeys: effectiveness in combination with oxytocin. Am J Obstet Gynecol 160 (1989) 45-47
25. Haluska G.J., Stanczyk F.Z., Cook M.J., and Novy M.J. Temporal changes in uterine activity and prostaglandin response to RU 486 in rhesus macaques in late gestation. Am J Obstet Gynecol 157 (1987) 1487-1495
26. Sitruk-Ware R., and Spitz I.M. Pharmacological properties of mifepristone: toxicology and safety in animal and human studies. Contraception 68 (2003) 409-420
27. Heikinheimo O., Kekkonen R., and Lahteenmaki P. The pharmacokinetics of mifepristone in humans reveal insights into differential mechanisms of antiprogestin action. Contraception 68 (2003) 421-426